Acorah Software Products - Accounts Production 16.3.350 false true 31 December 2023 1 January 2023 false 1 January 2024 31 December 2024 31 December 2024 10982762 Mr Bhaval Patel Mr Sanjay Patel iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 10982762 2023-12-31 10982762 2024-12-31 10982762 2024-01-01 2024-12-31 10982762 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2024-12-31 10982762 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 10982762 frs-core:LandBuildings frs-core:OwnedOrFreeholdAssets 2023-12-31 10982762 frs-core:ShareCapital 2024-12-31 10982762 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 10982762 frs-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 10982762 frs-bus:FilletedAccounts 2024-01-01 2024-12-31 10982762 frs-bus:SmallEntities 2024-01-01 2024-12-31 10982762 frs-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 10982762 frs-bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 10982762 frs-core:CostValuation 2023-12-31 10982762 frs-core:CostValuation 2024-12-31 10982762 frs-core:ProvisionsForImpairmentInvestments 2023-12-31 10982762 frs-core:ProvisionsForImpairmentInvestments 2024-12-31 10982762 frs-bus:Director1 2024-01-01 2024-12-31 10982762 frs-bus:Director2 2024-01-01 2024-12-31 10982762 frs-countries:EnglandWales 2024-01-01 2024-12-31 10982762 2022-12-31 10982762 2023-12-31 10982762 2023-01-01 2023-12-31 10982762 frs-core:CurrentFinancialInstruments 2023-12-31 10982762 frs-core:ShareCapital 2023-12-31 10982762 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31
Registered number: 10982762
Pharma Holdings Limited
Financial Statements
For The Year Ended 31 December 2024
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2—4
Page 1
Balance Sheet
Registered number: 10982762
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 122,747 122,747
Investments 5 1,551,427 1,551,427
1,674,174 1,674,174
CURRENT ASSETS
Debtors 6 - 1,197
Cash at bank and in hand 25 -
25 1,197
Creditors: Amounts Falling Due Within One Year 7 (866,409 ) (866,445 )
NET CURRENT ASSETS (LIABILITIES) (866,384 ) (865,248 )
TOTAL ASSETS LESS CURRENT LIABILITIES 807,790 808,926
NET ASSETS 807,790 808,926
CAPITAL AND RESERVES
Called up share capital 4 4
Profit and Loss Account 807,786 808,922
SHAREHOLDERS' FUNDS 807,790 808,926
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Sanjay Patel
Director
11 March 2025
The notes on pages 2 to 3 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
Pharma Holdings Limited is a private company, limited by shares, incorporated in England & Wales, registered number 10982762 . The registered office is 39 Bromley Road, London, SE6 2TS.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Freehold No depreciation
2.3. Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts
2.4. Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. 
2.5. Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably. 
3. Average Number of Employees
Average number of employees, including directors, during the year was: 2 (2023: 2)
2 2
4. Tangible Assets
Land & Property
Freehold
£
Cost
As at 1 January 2024 122,747
As at 31 December 2024 122,747
Net Book Value
As at 31 December 2024 122,747
As at 1 January 2024 122,747
Page 2
Page 3
5. Investments
Subsidiaries
£
Cost
As at 1 January 2024 1,551,427
As at 31 December 2024 1,551,427
Provision
As at 1 January 2024 -
As at 31 December 2024 -
Net Book Value
As at 31 December 2024 1,551,427
As at 1 January 2024 1,551,427
Details of investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:
Undertaking                                                Holding             Proporation of voting rights &shares
Subsidiary undertakings
Health Care Limited                               Ordinary shares           100%
Registered office
39 Bromley Road, London, England, SE6 2TS 
Principal activity :  Dispensing chemist in specialised stores .
The profit for the financial period Health Care Limited  was £251,570 and the aggregate amount of capital and reserve at the end of the period was £946,450
6. Debtors
2024 2023
£ £
Due within one year
Other debtors - 1,197
7. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Trade creditors - 36
Other creditors 866,409 866,409
866,409 866,445
8. Related Party Transactions
Mr Sanjay Patel and Mr Bhaval Patel are directors of the company. 
At the end of the year amount owed by the company to the directors is £265.20 (2023: 265.20).
During the year the company has declared dividends of £0.00. (2023: 0.00).
9. Summary of transactions with other related parties and subsidiaries
Page 3
Page 4
BU Patel Limited
(Company associated with the directors)
Mr Bhaval Patel is also the director of BU Patel Limited.
At the balance sheet date, the amount due to BU Patel Limited was £432,000.00
Black Panda Limited
(Company associated with the directors)
Mr Sanjay Patel is also the director of Black Panda Limited.
At the balance sheet date, the amount due to Black Panda Limited was £432,000.00
Summary of transactions with subsidiaries
Health Care Limited
(100% subsidiary undertaking of the Pharma Holdings Limited)
At the balance sheet date, the amount due to Health Care Limited was £2,144.00 (2023: £0.00)
Page 4